Cerebral atherosclerosis, including intracranial cerebral atherosclerosis (ICAS) and extracranial cerebral atherosclerosis (ECAS), is an important risk factor for stroke. 1,2 Comparing ECAS and ICAS, ICAS has been reported to increase the risk of stroke and stroke-related morbidity or mortality, especially in Asian populations. 2 Therefore, it is important to find and manage risk and association factors not only for ECAS but also ICAS in Asian stroke patients. However, risk factors or association factors for the presence of ICAS have been not completely elucidated. Currently, old age, hypertension, diabetes mellitus, hyperlipidemia, alcohol intake, smoking, and increased body mass index are factors associated with ICAS, but these factors are also associated with ECAS. 3, 4 Interarm blood pressure difference (IABD) is common in various populations. Generally, IABD ≥10 mm Hg is noted in 4.4% of subjects without vascular disease, but the prevalence increases to 7.0% in diabetes, 10.3% in stroke, and 13.6% in patients with hypertension. 5, 6 IABD is independently related to all-cause and cardiovascular mortality, 7 and these associations are also seen even in cohorts without preexisting cardiovascular disease. 8 Atherosclerosis is a systemic disease and the IABD may be related to atherosclerosis of the aorta and its branches, especially the subclavian artery. 9 Moreover, IABD is associated with increased arterial stiffness in community-dwelling elderly, 10 and this arterial stiffness is positively correlated with the presence of ICAS. 11 However, studies that confirm the relationship between IABD and ICAS or ECAS in stroke patients are lacking. In this study, we hypothesized that IABD would be associated with the presence and burden of ICAS or ECAS in noncardioembolic stroke patients.
2012 and December 2015, 1,798 consecutive patients with acute cerebral infarction or transient ischemic attack within 7 days after symptom onset were admitted to our stroke center. 12 During hospitalization, all patients were thoroughly evaluated and their demographic data, medical history, clinical manifestations, and vascular risk factors were recorded. According to the standard protocol of our stroke center, all patients underwent brain computed tomography and/or magnetic resonance imaging, vascular imaging studies (digital subtraction angiography, magnetic resonance angiography, or computed tomography angiography), chest radiography, 12-lead electrocardiography, and routine blood tests. An ankle-brachial index (ABI) study was also performed as part of the routine examination within 7 days after admission using an automated device (VP-1000; Colin, Komaki, Japan). 12 Among the 1,798 patients, those with any potential cardiac source of embolism (n = 295; persistent atrial fibrillation/ flutter (n = 224), paroxysmal atrial fibrillation (n = 40), sick sinus syndrome (n = 5), and other potential cardiac source of embolism (n = 26)), stroke due to other determined causes (rare causes, n = 43), incomplete stroke evaluation (n = 17), or transient ischemic attack (n = 198) were excluded. Patients with potential cardiac source of embolism were excluded because arrhythmia can prevent accurate measurement of blood pressure and brachial ankle pulse wave velocity. 6, 13 Moreover, steno-occlusive lesions due to atherosclerosis are often indistinguishable from those due to cardiac embolism. 6, 13 Then, patients without brain magnetic resonance imaging (n = 31) because of patient refusal, claustrophobia, or the presence of metallic substances in the body, without cerebral intravascular and extravascular images (n = 11), and those with poor image quality (n = 6) were also excluded. Additionally, patients who did not have ABI performed (n = 72) or who showed low (<0.9) ABI (n = 62), which may cause inaccurate measurement of blood pressure and brachial ankle pulse wave velocity, 14 were also excluded. Finally, 1,063 patients were included in this study (Supplementary Figure 1) . Stroke classification was determined based on the Trial of Org 10172 in Acute Stroke Treatment classification system. 15 A detailed definition of hypertension, diabetes mellitus, hyperlipidemia, smokers, previous stroke, coronary artery disease, metabolic syndrome, alcohol intake, and left ventricular hypertrophy were described in a previous study and Supplemental Methods. 16, 17 Our study was approved by our Institutional Review Board of our hospital, and patient informed consent was waived because of the study's retrospective, cross-sectional nature.
Measurement of blood pressure in both arms and IABDs
The detailed methods for investigating IABD are described elsewhere. 6 In brief, systolic and diastolic blood pressure was measured in both arms during the admission period in the supine position using an automated device which was primarily designed to calculate ABI. Arterial blood pressure was simultaneously checked with pressure cuffs wrapped on both brachial arteries and posterior tibial arteries by the oscillometric method. 18 The systolic and diastolic blood pressures in both arms were measured once. The presence of large systolic IABD (IASBD) and large diastolic IABD (IADBD) were defined as the absolute interarm difference of systolic blood pressure ≥10 mm Hg which was a frequently used cutoff in previous studies for large IASBD and IADBD. 6, 19 The brachial ankle pulse wave velocity was calculated as mean value of bilateral brachial ankle pulse wave velocity.
Brain MR protocol and definition of cerebral atherosclerosis
The detailed protocol of brain magnetic resonance imaging and MRA was described in previous study. 16 In brief, all MRA examinations were performed with a 1.5T imaging unit (MAGNETOM, Avanto 1.5 T; Siemens Medical Solutions, Erlangen, Germany). The MRA for evaluating ICAS consisted of a protocol of 3-dimensional time-offlight sequences. The degree of ICAS stenosis was measured as described previously, 20 and the presence and burden of ICAS were defined as a ≥50% decrease in luminal diameter. 11 ECAS was investigated in the bilateral carotid artery at the bifurcation level as described in the North American Symptomatic Carotid Endarterectomy Trial, 21 and the presence of ECAS was defined as a ≥50% decrease in luminal diameter. Extracranial vertebral arteries were not included in the data analysis because a normal variant of vertebral artery hypoplasia cannot be clearly differentiated from acquired stenosis by MRA. 3 If one artery had multiple stenotic lesions, the most severe lesion was selected. 11 The burden of ICAS and ECAS were defined as the summation of the number of lesions from each intracranial and extracranial cerebral artery. The presence of ICAS and ECAS were independently investigated by 2 neurologists (T.J.S. and Y.C.) blinded to clinical information. The Kappa value for interobserver agreement regarding the presence of ICAS was 0.936. Consensus was reached in cases of discrepancy for detection of ICAS and ECAS.
Statistical analysis
Statistical analyses were performed using the Windows SPSS software package (version 21.0, Chicago, IL). Continuous variables are expressed as mean ± SD, and categorical variables are expressed as frequency and percentage. To compare demographic characteristics and clinical variables according to presence of cerebral atherosclerosis, the Chi-square test, 1-way analysis of variance, and Kruskal-Wallis test were performed. To compare demographic characteristics and presence of vascular risk factor differences between IASBD and IADBD ≥10 mm Hg and <10 mm Hg patients, the Chi-square test, independent t-test, and Fisher's exact test were performed. The association of IASBD and IADBD ≥10 with ECAS and ICAS burden was investigated with linear-by-linear association analysis. The relationship between the existence of IASBD and IADBD and cerebral atherosclerosis was investigated by multivariate binary logistic regression with each presence of ECAS, ICAS, and both ECAS and ICAS as dependent variables after controlling for gender, age, and variables with a P value <0.1 in univariate analysis. Because of multicollinearity between cerebral atherosclerosis and stroke classification, we did not 
RESULTS

Demographics and comparisons of cerebral atherosclerosis
Demographic data and frequency of risk factors were not different except for age between patients who were included and those who were excluded (Supplementary Table 1) . In all included patients, 62.4% (663/1063) were male and the mean age was 64.8 ± 11.6 years. ICAS only, ECAS only, and both ECAS and ICAS were noted in 23.0% (245/1063), 13.4% (142/1063), and 8.1% (86/1063) of patients, respectively. Compared to those without cerebral atherosclerosis, patients with cerebral atherosclerosis were older and had more frequent histories of hypertension, diabetes mellitus, coronary artery disease, left ventricular hypertrophy, large artery atherosclerosis stroke subtype, increased brachial ankle pulse wave velocity, IASBD ≥10 mm Hg and IADBD ≥10 mm Hg. Moreover, patients with cerebral atherosclerosis took antihypertensive medication and lipid lowering agents less frequently (Table 1 ). In total, 121 (11.4%) patients underwent antihypertensive treatment after admission. Among these Table 2 . Clinical characteristics and comparison of study patients according to IABD ≥ 10 mm Hg Data are shown as n (%) or mean ± SD. Abbreviations: ABI, ankle-brachial index; baPWV, brachial ankle pulse wave velocity; DBP, diastolic blood pressure; IABD, interarm blood pressure difference; IADBD, interarm diastolic blood pressure difference; IASBD, interarm systolic blood pressure difference; SBP, systolic blood pressure.
121 patients, 86 (71.1%) required intravenous labetalol only, while 12 (9.9%) required intravenous labetalol and perdipine therapy. Moreover, 13 (10.7%) patients received intravenous labetalol and oral antihypertensive agents, and another 10 (8.3%) patients received oral antihypertensive agents only for the acute ischemic stroke condition.
Patients with IASBD ≥10 mm Hg and IADBD ≥10 mm Hg were noted in 9.4% (100/1063) and 5.3% (56/1063) of patients, respectively. Patients with IASBD ≥10 mm Hg were older and had a more frequent history of diabetes mellitus, left ventricular hypertrophy and increased brachial ankle pulse wave velocity compared to those with IASBD <10 mm Hg. There were no differences in demographics and risk factors between patients with IADBD ≥10 mm Hg and <10 mm Hg (Table 2) .
Association between cerebral atherosclerosis and IABD
The patients with IASBD ≥10 mm Hg were more frequently burdened with ICAS (P = 0.001) and ECAS (P = 0.027). Patients with IADBD ≥10 mm Hg were also more frequently burdened with ICAS (P = 0.042) but not ECAS (P = 0.187) (Figure 1 ). Multivariate analysis after controlling for gender, age, and a P value <0.1 in univariate analysis (gender, age, body mass index, hypertension, diabetes mellitus, coronary artery disease, antithrombotics, antihypertensive agents, lipid lowering agents, left ventricular hypertrophy, brachial ankle pulse wave velocity) showed IASBD ≥10 mm Hg was independently associated with the presence of both ECAS and ICAS [odds ratio (OR): 2.96, 95% confidence interval (CI): 1.65-5.31, P = 0.001]. As IASBD increased by 1 mm Hg, the presence of both ECAS and ICAS also increased (OR: 1.03, 95% CI: 1.01-1.06, P = 0.015). Moreover, IASBD ≥15 mm Hg was independently associated with ICAS only (OR: 2.22, 95% CI: 1.01-4.93, P = 0.015). IADBD ≥10 mm Hg was independently associated with the presence of ICAS only (OR: 1.87, 95% CI: 1.03-3.37, P = 0.037). Each IADBD increase by 1 mm Hg was associated with an increase in ICAS only (OR: 1.05, 95% CI: 1.01-1.09, P = 0.004). Patients with both IASBD and IADBD ≥10 mm Hg was independently related with presence of ICAS (OR: 2.68, 95% CI: 1.20-5.97, P = 0.015). There were no significant associations between IASBD, IADBD, and the presence of ECAS only regardless of any blood pressure difference cutoff value (Table 3) . Furthermore, the association between IASBD, IADBD ≥10 mm Hg, 15 mm Hg, and presence of cerebral atherosclerosis was consistently noted regardless of antihypertensive treatment after admission (Supplementary Table 2 ).
DISCUSSION
In this study, IASBD >10 mm Hg was associated with the presence and burden of both ECAS and ICAS. In addition, if the IASBD did not exceed 15 mm Hg, its association with ICAS only was not demonstrated. IADBD >10 mm Hg was independently associated with ICAS only presence and burden. Thus, this study showed that IASBD and IADBD were diversely associated with cerebral atherosclerosis. A previous study in Chinese patients with no history of stroke showed a diverse association of IASBD/IADBD difference with ECAS/ ICAS. 22 Our results support the results of this previous study and present new and additional information in a similar Asian noncardioembolic acute cerebral infarction patient cohort with respect to the relationship between IABD and cerebral atherosclerosis. 6 In addition, our study suggests the possibility of utilizing bi-brachial blood pressure measurements as a screening tool that can be easily obtained in clinical practice to estimate the presence and burden of cerebral atherosclerosis in acute noncardioembolic stroke patients.
Contrary to our study, a previous study on stroke patients showed no significant association between IABD and cerebral atherosclerosis. 6 This previous study included patients with transient ischemic attack and did not exclude hypoplasia of the vertebral artery, which is an important confounding factor. 6 Differences in these methods can help explain the differences in our findings. Furthermore, in our study, IASBD ≥5 mm Hg was not associated with cerebral atherosclerosis. In previous studies, IASBD ≥5 mm Hg was associated with target organ damage in patients with type 2 diabetes mellitus and was related with cardiovascular mortality and peripheral arterial disease in patients who took aspirin for asymptomatic atherosclerosis. 23, 24 The reason for this discrepancy from our results is probably differences in the study population or design; therefore, further prospective studies are needed to confirm the association and causality.
The mechanisms that can explain the results of this study are unclear. However, it may be explained by some hypotheses. First, increased arterial stiffness can help explain the results of this study. In a previous population-based study, IASBD >10 mm Hg was associated with arterial stiffness. 10 Furthermore, increased arterial stiffness was not associated with ECAS and was associated with ICAS in acute ischemic stroke patients. 11 These findings partially support our findings. Second, large IABD may be related to upper limb ischemia resulting from atherosclerosis and subclavian artery stenosis. 7 Thus, large IABD could be associated with poorer blood flow and perfusion to the upper extremities, including the brain. 25 This long-standing cerebral hypoperfusion may induce oxidative stress to cerebral organs including the vasculature 26 and this oxidative stress could lead to the attenuation of endothelial function through decreased production of nitric oxide and increased destruction of nitric oxide by superoxide. 27 Asymmetric-dimethylarginine, which is an endogenous inhibitor of endothelial nitric oxide, was associated with ICAS. 28 Third, classical vascular risk factors, such as hypertension, diabetes, hyperlipidemia, and accompanying vascular inflammation, are well known risk factors not only for coronary, peripheral, innominate, and subclavian atherosclerosis, but also for cerebral atherosclerosis. As mentioned above, vascular stenosis of the innominate artery and subclavian artery can cause IABD. 29 Therefore, the association between cerebral atherosclerosis and IABD in our study might be an epiphenomenon from systemic atherosclerosis caused by a common vascular risk factor. Fourth, left ventricular hypertrophy an important risk factor for carotid artery stenosis and plaques. 30 Left ventricular hypertrophy is also independently associated with large IASBD. 31 Although a causal-relationship is difficult to explain, IABD and cerebral atherosclerosis could involve resistance in the flow of blood to the brain and this resistance may aggravate left ventricular hypertrophy. Reciprocally, this progressed left ventricular hypertrophy may also induce or exacerbate cerebral atherosclerosis via increasing shear stress. To confirm these hypotheses, further study is needed.
In this study, IADBD was associated with presence and burden of ICAS only. Similar to IASBD, the IADBD is also common, though there have limited studies regarding the association between IADBD and cerebral atherosclerosis. Left ventricular mass index has been independently associated with IADBD but not with IASBD in the general population. 32 In another study, IADBD (but not IASBD) induced by one arm ischemia was associated with arm flow-mediated dilatation, which was an early index of an arterial endothelium lesion. 33 As mentioned above, these endothelial dysfunctions are closely related to ICAS 28 and this mechanism may explain our study's results. On the contrary, in a study of type 2 diabetes mellitus patients, IADBD was not associated with target organ damage. 23 These differing results from our study can be explained by subject size, study population, and frequency of demographics or risk factors. Furthermore, our study showed relatively small IADBD (less than 1 mm Hg) in 4 subgroups of cerebral atherosclerosis. Since this small IADBD can vary from measurement to measurement, careful interpretation of the relationship between IADBD and cerebral atherosclerosis is needed. This study has some limitations. First, although consecutive patients were included and ABI was routinely performed in almost all patients, this study may have a selection bias because of its retrospective design. Second, the population in this study was limited to acute ischemic stroke patients and only Korean patients. Risk factors and patterns of cerebral atherosclerosis are different between Asian and Western populations. Therefore, it is difficult to generalize our findings to other populations or cohorts. Third, we could not measure the muscle tone (spasticity or flaccidity) of both arms, which can influence IABD. Lastly, for accurate IABD measurements, simultaneous, automatic, and multiple assessment is recommended rather than sequential, manual, and one-time evaluation methods. 34, 35 Although our study used simultaneous measurement with an automatic device, IABD was measured only once while performing ABI. Thus, the consistency of the measurements for IABD is unknown.
In conclusions, the IASBD ≥10 mm Hg was associated with both ECAS and ICAS presence and burden. IASBD ≥15 mm Hg and IADBD >10 mm Hg were independently associated with the presence and burden of ICAS only. In noncardioembolic stroke patients with IASBD ≥10 or IADBD ≥10, the possibility of accompanying cerebral atherosclerosis should be considered.
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